Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EXL 01

Next Previous
Drug Profile

EXL 01

Alternative Names: EXL-01

Latest Information Update: 17 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exeliom Biosciences
  • Class Anti-inflammatories; Antibacterials; Antineoplastics; Bacteria
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators; Interleukin 10 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Crohn's disease
  • Phase I/II Clostridium difficile infections; Non-small cell lung cancer
  • Preclinical Gastric cancer; Liver cancer; Ulcerative colitis

Most Recent Events

  • 13 Mar 2025 Phase-II clinical trials in Crohn's disease (Prevention) in France (PO) (NCT06925061)
  • 02 Oct 2024 Exeliom Biosciences terminates the phase-I MAINTAIN trial in Crohn's disease in Belgium and Poland due to low recruitment (PO), (NCT05542355)
  • 16 Jul 2024 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, Combination therapy, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in France (PO) (NCT06448572)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top